Compare Quest Diagnostics Inc (DGX) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Koninklijke Philips NV — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.48B), while Koninklijke Philips NV trades at $24.51 (market cap $23.52B). The key difference: Quest Diagnostics Inc and Koninklijke Philips NV are close in size by market cap, and Koninklijke Philips NV pays the higher dividend (4.17%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Koninklijke Philips NV for 84 Days on average.
| DGX | PHG | |
|---|---|---|
Market Cap | $25.48B | $23.52B |
Volume | 941,866 | 1,635,069 |
Sector | Health | Health |
52-Week High | $247.45 | $32.91 |
52-Week Low | $173.49 | $23.81 |
Typical Hold Time | 56 Days | 84 Days |
Enterprise Value | $31.23B | $29.87B |
Dividend Yield | 1.49% | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.
The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.
PHG trades at $24.09, down 0.25% on the day, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operational cash flow of $1.17B. Recent news highlights product innovations including new CT systems and AI healthcare tools, while institutional investors like Bank of America and Arrowstreet Capital have increased positions.
PHG presents a mixed outlook with solid profitability recovery but technical weakness. The stock offers value at reasonable valuations (P/E 18.84, P/S 1.18) and analyst consensus leans Hold (63.64%). Key risks include cybersecurity threats (Reuters, 2026-08-13) and debt levels, while opportunities lie in healthcare technology expansion and Exor's potential increased stake to 22% (Reuters, 2026-08-11).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
